Caraco Pharmaceutical Laboratories, Ltd. was founded in 1984 and is based in Detroit, Michigan. Caraco Pharmaceutical Laboratories, Ltd. is a subsidiary of Sun Pharmaceutical Industries Limited. Caraco Pharmaceutical Laboratories, Ltd. (Caraco) is engaged in the business of developing, manufacturing, marketing and distributing generic and private-label pharmaceuticals to wholesalers, distributors, warehousing and non-warehousing chain drugstores and managed care providers, throughout the United States and Puerto Rico. During the fiscal year ended March 31, 2009 (fiscal 2009), Caraco received United States Food and Drug Administration (FDA) approval for eight abbreviated new drug applications (ANDAs) relating to three products. It had filed 10 ANDAs relating to nine products with the FDA during fiscal 2009. This brings Caraco’s total number of ANDAs pending approval by the FDA to 29 (including four tentative approvals) relating to 25 products as of March 31, 2009.

Peoplesway.Com, Inc., an electronic commerce and Internet services company, maintains an Internet destination called ‘Peoplesway’, located at www.peoplesway.com. The majority of the company’s goods and services are available through an alliance with DRM, Inc. and its member network of approximately 14,000 independent contractors. The Web site offers goods and services for sale, such as personal hygiene products, skin care, hair care, and bath products. In addition, DRM supplies Body Management System nutritional products, including weight loss and anti-aging supplements. DRM manufactures and packages these products through a licensing agreement with a health and beauty product manufacturer.

Avexa discovers drugs to treat vexing ailments. The pharmaceutical and research company works on the discovery and development of drugs for the treatment of infectious diseases, specifically HIV and antibiotic-resistant strains of bacteria. Avexa has worked on collaborative projects with Victorian College of Pharmacy, The Shanghai Institute of Organic Chemistry, North Carolina State University, and Georgetown University, among other institutions. The company was formed in 2004 when it was spun off from Australian drug discovery and biotechnology development company Amrad. Plans to merge with drugmaker Progen Pharmaceutical were canceled in 2009.

Henderson Morley takes aim at those pesky microscopic parasites we know as viruses. The company researches and develops vaccines and treatments for viral infections by preventing them from replicating once they invade their host cells. One of its lead product candidates is a vaccine for genital herpes that could be used as a preventative or a therapeutic measure. Other candidates target human cytomegalovirus and human papillomavirus. Instead of taking its candidates through all phases of development, Henderson Morley instead looks to out-license its candidates. Chairman Andrew Knight owns 34% of the company.

Fulcrum Pharma plc is a United Kingdom-based company. The Company is engaged in providing solutions for the development of therapeutic products. It provides regulatory expertise and resource throughout all stages of product development. The Company provides customized pharmacovigilance and risk management solutions. It provides support for product registration, launch and in market maintenance. It operates through eight offices across the United States, Europe and Japan. The Company’s subsidiaries include Fulcrum Pharma (Europe) Limited, Fulcrum Pharma Developments Limited, Quadramed Limited, Unicus Limited and Fulcrum Regulatory Limited.

Network Biosystems develops high throughput DNA sequencing systems with applications in the personalized medicine, forensics, drug discovery, and security arenas. The company blends nanotechnology and mircrofluidics to achieve its DNA analysis. Its sequencing systems were conceived at MIT's Whitehead Institute. The company is in the developmental stage and is pursuing a variety of commercial applications including manufacturing a rugged portable STR analysis and identification in the forensics field and on site screening of large numbers for use by homeland security.

CombiMatrix Corporation company was founded in 1995 and is based in Mukilteo, Washington. CombiMatrix Corporation, together with its subsidiaries, develops technologies, products, and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology, defense, and homeland security. Its technologies include a platform to produce user-defined, in-situ synthesized, and oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations, and proteins in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences, and nanotechnology.CombiMatrix Corporation's products and services include CustomArray platform, an oligonucleotide array for genetic studies; CatalogArray Microarrays for gene expression studies, mutation analysis, and other studies; Micro-RNA Arrays that are used to study micro-RNA molecules; DNA Array Synthesizer, an instrument that enables researchers to fabricate DNA arrays to their specifications; stripping reagents, which enable researchers to re-use microarrays; ElectraSense Reader, an electrochemical scanning instrument; and comparative genomic hybridization arrays, which are used for research and molecular diagnostic applications. CombiMatrix Corporation also offers proprietary molecular synthesis and screening methods for the discovery of potential new drugs. In addition, the company develops capabilities of producing arrays that utilize bacterial artificial chromosomes that enable genetic analysis; and a series of compounds to address various oncology-related diseases. It sells its products and services directly, with partners, and through distributors to customers in the United States, Europe, and Asia.

Theravance was founded in 1996 and is headquartered in South San Francisco, California. Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines across various therapeutic areas, including respiratory disease, bacterial infections, and gastrointestinal motility dysfunction. It offers Telavancin (cSSSI), a bactericidal injectable antibiotic for the treatment of complicated skin and skin structure infections; Telavancin (HAP) that is used to treat hospital-acquired pneumonia or nosocomial pneumonia; and Horizon to develop and commercialize long-acting beta2 agonist (LABA) product candidate as a single agent new medicine for the treatment of chronic obstructive pulmonary disease (COPD) and as part of a new combination medicine with an inhaled corticosteroid (ICS) for the treatment of asthma and/or a long acting muscarinic antagonist (LAMA) for COPD. In addition, it offers GSK961081, a bifunctional muscarinic antagonist-beta2 agonist compound, which is in phase 2 clinical studies; and TD-5108, a gastrointestinal motility dysfunction program for the treatment of chronic constipation and other disorders related to reduced gastrointestinal motility. The company has collaboration arrangements with Astellas Pharma, Inc. for the development and commercialization of Telavancin; GlaxoSmithKline plc to develop and commercialize LABA product candidates; and AstraZeneca AB to develop and commercialize intravenous anesthetic compounds. The company also has a strategic alliance with GlaxoSmithKline plc. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002.

LifeSpan BioSciences likes the way genes express themselves. The firm helps drugmakers develop new product candidates faster by finding proteins and RNA in human tissue samples to identify gene expression associated with disease. It licenses access to its databases of gene expressions and protein localizations to drug developers. Also available are target validation and tissue pathology services. LifeSpan's clients include pharmaceutical companies in Asia, Europe, and North America.

Cellectis SA company develops technologies involving the research and development of rational genome engineering (making changes in the genetics of a cell or organism). The company's research is primarily based on the Meganucleasus, a natural classification of DNA that isolates unique breaks at key locations within living cells. Its patented Meganuclease Recombination Systems technology helps to initiate the rational genome engineering process, which in turn can help treat diseases and augment genetic codes.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.